Eagle Health Investments LP cut its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 21.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 339,764 shares of the medical research company's stock after selling 91,550 shares during the period. Natera makes up 13.2% of Eagle Health Investments LP's holdings, making the stock its largest position. Eagle Health Investments LP owned approximately 0.26% of Natera worth $53,785,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in Natera by 43.7% in the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after buying an additional 2,036,396 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Natera by 205.4% in the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock valued at $355,493,000 after buying an additional 1,883,481 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Natera in the fourth quarter worth about $146,419,000. Vanguard Group Inc. grew its holdings in Natera by 7.7% during the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after acquiring an additional 879,463 shares during the period. Finally, PointState Capital LP lifted its holdings in Natera by 112.0% in the third quarter. PointState Capital LP now owns 782,538 shares of the medical research company's stock valued at $99,343,000 after acquiring an additional 413,468 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.
Natera Trading Down 3.3 %
NTRA stock traded down $4.81 during trading on Monday, reaching $139.13. 846,897 shares of the stock were exchanged, compared to its average volume of 1,362,937. The firm has a market capitalization of $18.81 billion, a price-to-earnings ratio of -79.21 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The business has a 50 day moving average price of $159.60 and a 200-day moving average price of $151.13. Natera, Inc. has a 1 year low of $83.13 and a 1 year high of $183.00.
Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. On average, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.
Analyst Ratings Changes
NTRA has been the topic of a number of analyst reports. Morgan Stanley raised their price objective on shares of Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. lifted their target price on shares of Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. Canaccord Genuity Group reissued a "buy" rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Piper Sandler raised their price target on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Finally, The Goldman Sachs Group lifted their price objective on Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $178.12.
Check Out Our Latest Stock Report on Natera
Insider Buying and Selling
In other news, insider John Fesko sold 663 shares of Natera stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares of the company's stock, valued at approximately $27,739,941.88. The trade was a 0.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the transaction, the chief executive officer now directly owns 267,629 shares in the company, valued at approximately $44,150,756.13. The trade was a 22.69 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 306,797 shares of company stock valued at $48,940,883. 7.60% of the stock is currently owned by insiders.
Natera Profile
(
Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
See Also
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
